Comparison of investigator-initiated and industry-initiated trials in Canada and other countries.

Abstract

464 Background: Investigator-initiated trials (IITs) developed by academic investigators without inherent commercial interests have contributed significantly to oncology. However, costs and regulatory complexity may negatively impact IITs. Little is published about current trends in cancer IITs. We focused on IITs in genitourinary cancers (GU IITs) in Canada and other countries and compared these to industry-initiated trials conducted over the same time period. Methods: We collected data using searches of the ClinicalTrials.gov registry for bladder, kidney, and prostate cancer trials conducted in Canada, US, and France from 2007 to 2017. IITs were defined as trials funded by individuals, un..